Table 2.

Candidate missense mutations identified in the VWD3 3WINTERS-IPS cohort

EU/IRVWF Gene DefectDomain
(exon)
SIFTPoly Phen-2Mutation TasterCADD PHRED scoreClinGendbSNP(re) –HGMD (CM)First
reported
In vitro
study
IR NM_000552.3: c.220G>A; p.Gly74Arg D1 (3) 33 VUS –   
EU NM_000552.3:c.449T>C; p.Leu150Pro D1 (5) 28 LP rs61753994 63 *  
IR NM_000552.3:c.498C>A; p.Asn166Lys D1 (5) 22.7 VUS –   
EU/IR NM_000552.3:c.823T>A; p.Cys275Ser D1 (7) 28.1 LP rs61753998 31  65  
IR NM_000552.3:c.1574G>A; p.Gly525Glu D2 (14) 26.6 VUS –   
EU NM_000552.3:c.2311A>G; p.Met771Val D' (18) 23 LP rs1212894308 - CM061227 44   
IR NM_000552.3:c.2376C>G; p.Cys792Trp D' (18) 26.4 LP –   
IR NM_000552.3:c.2560C>T; p.Arg854Trp D' (20) 31 LP rs61748482 64  64  
EU NM_000552.3:c.2771G>A; p.Arg924Gln D3 (21) 14.2 LB rs33978901 47  53,57  
EU NM_000552.3:c.3467C>T; p.Thr1156Met D3 (26) 26.2 LP rs267607328 65  66  
EU NM_000552.3:c.3568T>C; p.Cys1190Arg D3 (27) 27 LP rs61749364 50  67  
EU NM_000552.3:c.3679T>C; p.Cys1227Arg D3 (28) 28.7 LP rs61749366 68  67  
IR NM_000552.3:c.4007G>A; p.Arg1336Gln A1 (28) 21.8 VUS rs886049741   
EU NM_000552.3:c.5096C>T; p.Ser1699Phe A3 (29) 24.4 VUS – 46   
EU NM_000552.3:c.5146G>A; p.Ala1716Thr A3 (29) 20.8 VUS CM115145 rs61750623   
IR NM_000552.3:c.5429C>A; p.Ala1810Glu A3 (31) 7.8 VUS –   
EU NM_000552.3:c.5779T>C; p.Cys1927Arg D4 (34) 26.8 VUS CM930738 69 *  
IR NM_000552.3:c.6520T>G; p.Cys2174Gly D4 (37) 27.1 VUS rs61750619 31   
EU NM_000552.3:c.6551G>C; p.Cys2184Ser D4 (37) 25.8 LP CM125355 36 * 36  
EU NM_000552.3:c.6634T>C; p.Cys2212Arg D4 (38) 29 LP CM125353 36 * 36  
EU NM_000552.3:c.6697G>A; p.Glu2233Lys D4 (38) 27.9 VUS rs61750623 46   
EU NM_000552.3:c.6847T>C; p.Cys2283Arg C1 (39) 28 LP CM137380 70 * 70  
EU NM_000552.3:c.6911G>A; p.Cys2304Tyr C1 (40) 24.7 LP rs61750626 49  71  
EU NM_000552.3:c.6973T>A; p.Cys2325Ser C1 (40) 25.8 LP rs125608270 CM125358 36 * 36  
EU NM_000552.3:c.7085G>T; p.Cys2362Phe C2 (42) 27.6 P rs61750630 72 * 73  
EU NM_000552.3:c.7182T>G; p.Cys2394Trp§ C2 (42) 21.9 VUS CM095418 32 *  
EU NM_000552.3:c.7405T>C; p.Ser2469Pro C3 (43) 22.7 VUS rs61751287 49 *  
IR NM_000552.3:c.7619T>A; p.Val2540Asp C4 (45) 27.9 VUS –   
EU NM_000552.3:c.7636A>T; p.Asn2546Tyr C4 (45) 32 VUS rs61751298 74 *  
EU NM_000552.3:c.8012G>A; p.Cys2671Tyr§ C6 (49) 26.3 LP rs61751303 72 * 75  
EU NM_000552.3:c.8171G>A; p.Cys2724Tyr CK (51) 24.9 VUS –   
EU NM_000552.3:c.8216G>A; p.Cys2739Tyr CK (51) 26.6 LP rs61751305 76  75  
IR NM_000552.3:c.8323T>C; p.Ser2775Pro CK (52) 23.1 VUS –   
EU/IRVWF Gene DefectDomain
(exon)
SIFTPoly Phen-2Mutation TasterCADD PHRED scoreClinGendbSNP(re) –HGMD (CM)First
reported
In vitro
study
IR NM_000552.3: c.220G>A; p.Gly74Arg D1 (3) 33 VUS –   
EU NM_000552.3:c.449T>C; p.Leu150Pro D1 (5) 28 LP rs61753994 63 *  
IR NM_000552.3:c.498C>A; p.Asn166Lys D1 (5) 22.7 VUS –   
EU/IR NM_000552.3:c.823T>A; p.Cys275Ser D1 (7) 28.1 LP rs61753998 31  65  
IR NM_000552.3:c.1574G>A; p.Gly525Glu D2 (14) 26.6 VUS –   
EU NM_000552.3:c.2311A>G; p.Met771Val D' (18) 23 LP rs1212894308 - CM061227 44   
IR NM_000552.3:c.2376C>G; p.Cys792Trp D' (18) 26.4 LP –   
IR NM_000552.3:c.2560C>T; p.Arg854Trp D' (20) 31 LP rs61748482 64  64  
EU NM_000552.3:c.2771G>A; p.Arg924Gln D3 (21) 14.2 LB rs33978901 47  53,57  
EU NM_000552.3:c.3467C>T; p.Thr1156Met D3 (26) 26.2 LP rs267607328 65  66  
EU NM_000552.3:c.3568T>C; p.Cys1190Arg D3 (27) 27 LP rs61749364 50  67  
EU NM_000552.3:c.3679T>C; p.Cys1227Arg D3 (28) 28.7 LP rs61749366 68  67  
IR NM_000552.3:c.4007G>A; p.Arg1336Gln A1 (28) 21.8 VUS rs886049741   
EU NM_000552.3:c.5096C>T; p.Ser1699Phe A3 (29) 24.4 VUS – 46   
EU NM_000552.3:c.5146G>A; p.Ala1716Thr A3 (29) 20.8 VUS CM115145 rs61750623   
IR NM_000552.3:c.5429C>A; p.Ala1810Glu A3 (31) 7.8 VUS –   
EU NM_000552.3:c.5779T>C; p.Cys1927Arg D4 (34) 26.8 VUS CM930738 69 *  
IR NM_000552.3:c.6520T>G; p.Cys2174Gly D4 (37) 27.1 VUS rs61750619 31   
EU NM_000552.3:c.6551G>C; p.Cys2184Ser D4 (37) 25.8 LP CM125355 36 * 36  
EU NM_000552.3:c.6634T>C; p.Cys2212Arg D4 (38) 29 LP CM125353 36 * 36  
EU NM_000552.3:c.6697G>A; p.Glu2233Lys D4 (38) 27.9 VUS rs61750623 46   
EU NM_000552.3:c.6847T>C; p.Cys2283Arg C1 (39) 28 LP CM137380 70 * 70  
EU NM_000552.3:c.6911G>A; p.Cys2304Tyr C1 (40) 24.7 LP rs61750626 49  71  
EU NM_000552.3:c.6973T>A; p.Cys2325Ser C1 (40) 25.8 LP rs125608270 CM125358 36 * 36  
EU NM_000552.3:c.7085G>T; p.Cys2362Phe C2 (42) 27.6 P rs61750630 72 * 73  
EU NM_000552.3:c.7182T>G; p.Cys2394Trp§ C2 (42) 21.9 VUS CM095418 32 *  
EU NM_000552.3:c.7405T>C; p.Ser2469Pro C3 (43) 22.7 VUS rs61751287 49 *  
IR NM_000552.3:c.7619T>A; p.Val2540Asp C4 (45) 27.9 VUS –   
EU NM_000552.3:c.7636A>T; p.Asn2546Tyr C4 (45) 32 VUS rs61751298 74 *  
EU NM_000552.3:c.8012G>A; p.Cys2671Tyr§ C6 (49) 26.3 LP rs61751303 72 * 75  
EU NM_000552.3:c.8171G>A; p.Cys2724Tyr CK (51) 24.9 VUS –   
EU NM_000552.3:c.8216G>A; p.Cys2739Tyr CK (51) 26.6 LP rs61751305 76  75  
IR NM_000552.3:c.8323T>C; p.Ser2775Pro CK (52) 23.1 VUS –   

Variants reported in bold are not listed in the EAHAD,17  HGMD,18  or Ensembl19  databases. Variants reported in italics have been identified in both European and Iranian populations. Underlined variants might affect normal splice site.

SIFT (Sorting Intolerant From Tolerant): T = tolerated; D = deleterious. PolyPhen-2: D = probably damaging; P = possibly damaging; B = benign. MutationTaster: D = disease causing; N = polymorphism; A = disease-causing automatic. ClinGen: P = pathogenic; LP = likely pathogenic; LB = likely benign; VUS = uncertain significance. In Combined Annotation-Dependent Depletion (CADD), a cutoff of 20 was used so that variants with score ≥20 were considered harmful.21 

*

Indicates that the previous publication was concerning the same patient evaluated in this study.

Prediction already reported in ClinVar.

The pathogenicity of p.Arg1336Gln is unclear as it was found in the same allele together with c.2397_2400dupCATG, which implies that in this patient the p.Arg1336Gln does not play a role.

§

The second variants identified in this patient do not match the variant previously reported in the original publication of the patient.

Close Modal

or Create an Account

Close Modal
Close Modal